Source-grounded facts extracted from KORU Medical Systems, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
KORU Medical Systems, Inc. shareholders approved Ratification of the appointment of independent registered accountants for the 2026 fiscal year at the 2026-05-19 meeting.
“Proposal 5: Ratification of the appointment of independent registered accountants for the 2026 fiscal year. The Company’s shareholders ratified the appointment of Cherry Bekaert LLP as the company’s independent registered public accountants for the 2026 fiscal year.”
KORU Medical Systems, Inc. shareholders approved Advisory approval of the frequency of future votes on executive compensation at the 2026-05-19 meeting.
“Proposal 4: Advisory approval of the frequency of future votes on executive compensation. The Company’s shareholders, on an advisory basis, approved the frequency of future votes on executive compensation to be every one year.”
KORU Medical Systems, Inc. shareholders approved Advisory approval of the compensation of the Company’s executive officers at the 2026-05-19 meeting.
“Proposal 3: Advisory approval of the compensation of the Company’s executive officers. The Company’s shareholders, on an advisory basis, approved the compensation of the Company’s executive officers.”
KORU Medical Systems, Inc. shareholders approved Approval of an amendment to the 2024 Omnibus Equity Incentive Plan to increase the available number of shares at the 2026-05-19 meeting.
“Proposal 2: Approval of an amendment to the 2024 Omnibus Equity Incentive Plan to increase the available number of shares. The Company’s shareholders approved the amendment to the 2024 Omnibus Equity Incentive Plan to increase the available number of shares.”
KORU Medical Systems, Inc. shareholders approved Election of Directors at the 2026-05-19 meeting.
“Proposal 1: Election of Directors The nominees for director set forth under “Nominees” below were elected to the Company’s board of directors.”
KORU Medical Systems, Inc. reported first quarter ended March 31, 2026 results: revenue $11.8 million, net income $0.8 million, EPS ($0.02) per diluted share. Guidance reaffirmed.
“financial results for the first quarter ended March 31, 2026. The Company also reiterated guidance for the full year 2026. Recent Highlights ● First quarter 2026 net revenues of $11.8 million grew 22% over the prior year period ● First quarter 2026 gross profit grew 20% over the prior year period to $7.2 million, with gross margin of 61.5% ● First quarter 2026 net”
KORU Medical Systems, Inc. amended term loan of $5,000,000 with HSBC Ventures USA Inc. at 5.50% (floor) maturing December 1, 2029.
“USA Inc., as lender, dated March 8, 2024, as amended (the “Loan and Security Agreement”), relating to a revolving credit facility in an aggregate principal amount not to exceed $5,000,000 (the “Revolver”) and a term loan facility in an aggregate principal amount not to exceed $5,000,000 (the “Term Loan” and collectively with the Revolver, the “Credit Facility”).”
KORU Medical Systems, Inc. amended revolving credit of $5,000,000 with HSBC Ventures USA Inc. at 5.50% (floor) maturing March 30, 2028.
“The Amendment extends the maturity of the $5,000,000 Revolver from December 31, 2026 to March 30, 2028”
KORU Medical Systems, Inc. reported full year ended December 31, 2025 results: revenue $41.1 million, net income $2.6 million or ($0.06) per diluted share, EPS ($0.06) per diluted share. Guidance initiated.
“Total net revenues increased $7.5 million, or 22.2%, to $41.1 million, for the year ended December 31, 2025, as compared with the same period last year.”
KORU Medical Systems, Inc. reported fourth quarter ended December 31, 2025 results: revenue $10.9 million, net income $0.5 million or ($0.01) per diluted share, EPS ($0.01) per diluted share.
“quarter and full year ended December 31, 2025. The Company also initiated guidance for the full year 2026. Recent Highlights ● Fourth quarter 2025 net revenues grew 23% to $10.9 million; Full year 2025 net revenues grew 22% to $41.1 million ● Full year 2025 gross profit grew 20% to $25.6 million with gross margin of 62.3% ● Full year 2025 net loss of ($2.6)”
KORU Medical Systems, Inc.: Amended and restated bylaws to enhance procedural mechanics and disclosure requirements for stockholder nominations and proposals (effective 2026-02-05).
“Effective February 5, 2026, the Board of Directors (the “Board”) of KORU Medical Systems, Inc. (the “Company”) unanimously adopted a resolution to amend and restate the Company’s By-laws in connection with the Securities and Exchange Commission rules regarding universal proxy cards and a periodic review of the bylaws.”
KORU Medical Systems, Inc. amended Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, Inc. (effective 2024-01-01).
“On November 19, 2025, the Company entered into an Amended and Restated Manufacturing and Supply Agreement (the “Agreement”) with Command Medical Products, Inc. (“Command”)”
Kenneth Miller resigned as Chief Commercial Officer at KORU Medical Systems, Inc..
“On April 3, 2025, Kenneth Miller resigned his employment and position as Chief Commercial Officer of KORU Medical Systems, Inc. (the “Company”), effective immediately, to pursue a Chief Executive Officer role at an organization that does not compete with the Company.”
Brian Case was terminated as Chief Technology Officer at KORU Medical Systems, Inc..
“On July 18, 2024, the Company’s Board of Directors eliminated the position of Chief Technology Officer, currently held by Brian Case, effective as of September 16, 2024. Mr. Case’s employment with the Company will terminate concurrently with elimination of that position.”
KORU Medical Systems, Inc. shareholders approved Approval of the 2024 Omnibus Equity Incentive Plan at the 2024-05-09 meeting.
“Proposal 4: Approval of the 2024 Omnibus Equity Incentive Plan. The Company’s shareholders approved the adoption of the Company’s 2024 Omnibus Equity Incentive Plan. For Against Abstain Number of Shares 26,146,895 814,966 163,063”
KORU Medical Systems, Inc. shareholders approved Ratification of the appointment of independent registered accountants for the 2024 fiscal year at the 2024-05-09 meeting.
“Proposal 3: Ratification of the appointment of independent registered accountants for the 2024 fiscal year. The Company’s shareholders ratified the appointment of McGrail Merkel Quinn & Associates, P.C. as the company’s independent registered public accountants for the 2024 fiscal year. For Against Abstain Number of Shares 38,261,457 11,517 66,134”
KORU Medical Systems, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s executive officers at the 2024-05-09 meeting.
“Proposal 2: Approval, on an advisory basis, of the compensation of the Company’s executive officers. The Company’s shareholders, on an advisory basis, approved the compensation of the company’s executive officers. For Against Abstain Broker Non-Vote Number of Shares 26,409,104 541,923 173,897 11,214,184”
KORU Medical Systems, Inc. shareholders approved Election of Directors at the 2024-05-09 meeting.
“Proposal 1: Election of Directors The nominees for director set forth under “Nominees” below were elected to the Company’s board of directors. Number of Shares Nominees For Withheld Broker Non-Vote R. John Fletcher 25,929,278 1,195,646 11,214,184”
KORU Medical Systems, Inc. reported full year 2024 results: revenue $31.2 million to $32.2 million. Guidance reaffirmed.
“Reaffirmed full year 2024 revenue guidance of $31.2 million to $32.2 million, representing growth of 10% to 13% over the prior year.”
KORU Medical Systems, Inc. reported first quarter ended March 31, 2024 results: revenue 8.2 million, net income net loss of $1.9 million, EPS $(0.04) per diluted share.
“large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights ● First quarter 2024 net revenues of $8.2 million, an 11% increase over the prior year and record high quarterly revenues ● Core business (U.S. and International) growth of 14% over the prior year, driven by overall SCIg market”
KORU Medical Systems, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $28.5 million, net income ($13.7) million, or ($0.30) per share.
“issued guidance for the full year 2024. Recent Highlights ● Fourth quarter 2023 net revenues of $7.2 million, a 2% decrease from the prior year; Full year 2023 net revenues of $28.5 million, a 2% increase over the prior year ● Full year 6.7% Core business growth (U.S. and International) driven by overall SCIg market growth, share gains and expansion in new”
KORU Medical Systems, Inc. entered into Loan and Security Agreement with HSBC Ventures USA Inc. valued at $5,000,000 (effective 2024-03-08).
“On March 8, 2024, KORU Medical Systems, Inc. (the “Company”) entered into a loan and security agreement (the “Loan and Security Agreement”), by and between the Company and HSBC Ventures USA Inc., as lender providing for a revolving credit facility in an aggregate principal amount not to exceed $5,000,000 (the “Revolver”) and a term loan facility in an aggregate principal amount not to exceed $5,000,000”
KORU Medical Systems, Inc. reported full year 2023 results: revenue $28.0 to $28.5 million. Guidance reaffirmed.
“● Continued strategic, operational expense discipline, ending the quarter with $10.8 million in cash and cash equivalents ● Revised full year 2023 net revenue guidance to $28.0 to $28.5 million, reaffirmed gross margin guidance between 58%-60% for full-year and a planned Q4 exit between 60%-62%, and increased year-end cash balance guidance to greater”
KORU Medical Systems, Inc. reported third quarter ended September 30, 2023 results: revenue $7.0 million, net income $1.4 million, or $(0.03) per diluted share. Guidance reaffirmed.
“life for patients, today reported financial results for the third quarter ended September 30, 2023 and updates full year 2023 outlook. Highlights: ● Third quarter net revenue of $7.0 million, a 10% decline versus prior year ● Novel Therapies net revenue decline of $0.6 million was impacted primarily by a large clinical trial order in the prior year and timing of”
Kenneth Miller was appointed as Chief Commercial Officer at KORU Medical Systems, Inc..
“Kenneth Miller, age 55, has been appointed by KORU Medical Systems, Inc. (the “Company”) to serve in the newly created position of Chief Commercial Officer commencing November 6, 2023.”
Edward Wholihan was appointed as Director at KORU Medical Systems, Inc..
“On September 28, 2023, Edward Wholihan was appointed to the Board of Directors (the “Board”) of KORU Medical Systems, Inc. (the “Company”), filling the existing vacancy on the Board.”
KORU Medical Systems, Inc. reported full year 2023 results: revenue $31.0 - $32.5 million. Guidance lowered.
“Reducing full year 2023 net revenue guidance to $31.0 and $32.5 million, representing growth in the range of 11%-17% from prior guidance of $32.5 - $33.5 million, representing growth in the range of 17-20% ● Reaffirming 2023 gross margin between 58%-60% and a planned 2023 exit between 60%-62% ● Reaffirming cash balance at year-end 2023 greater than $10.0 million”
KORU Medical Systems, Inc. reported the second quarter ended June 30, 2023 results: revenue $6,935,930, net income $ 2.5 million, EPS $(0.05) per diluted share.
“2023 Second Quarter Financial Results Three Months Ended June 30, Change from Prior Year 2023 2022 $ % Net Revenues Domestic Core $ 5,388,172 $ 4,996,791 $ 391,381 $ 7.8% International Core 1,117,004 951,485 165,519 17.4% Novel Therapies 430,754 598,352 (167,598 ) (28.0)% Total $ 6,935,930 $ 6,546,628 $ 389,302 $ 5.9% Total net revenue increased $0.4 million, or 6%, for the three months ending June 30, 2023, compared to last year. Domestic Core growth of 8% was primarily driven by increased growth in consumables and pumps, new accounts, and increased prefilled syringe adoption. International Core growth of 17% was driven by strength across several EU markets, and growing global immunoglobulin drug volume availability. Novel Therapies net revenue declined by 28% in primarily related to strong non-recurring engineering revenues in the comparable quarter last year as well as the timing of 2023 pipeline wins. Gross profit increased $0.5 million or 16% in the three months ended June 30, 202”
KORU Medical Systems, Inc. reported second quarter ended June 30, 2023 results: revenue approximately $6.9 million. Guidance reaffirmed.
“revenues for the second quarter 2023 and provided business, outlook and executive updates. The Company reported total net revenues for the second quarter 2023 of approximately $6.9 million, representing growth of approximately 6% compared to the prior year period. Domestic Core revenues increased approximately 8%, International Core revenues increased approximately”
Thomas Adams was appointed as Chief Financial Officer at KORU Medical Systems, Inc..
“On and effective as of August 1, 2023, Thomas Adams, the Company’s Vice President of Financial Planning and Analysis and formerly interim Chief Financial Officer, was appointed as the Company’s Chief Financial Officer.”
Andrew D. C. LaFrence resigned as Chief Financial Officer at KORU Medical Systems, Inc..
“On and effective as of July 27, 2023, Andrew D. C. LaFrence, the Company’s Chief Financial Officer, resigned his employment for personal and family reasons.”
Thomas Adams changed role as Vice President of Financial Planning and Analysis at KORU Medical Systems, Inc..
“Thomas Adams, Interim Chief Financial Officer, will continue as the Company’s Vice President of Financial Planning and Analysis upon the appointment of Mr. LaFrence.”
Andrew D. C. LaFrence was appointed as Chief Financial Officer at KORU Medical Systems, Inc..
“Andrew D. C. LaFrence has been employed by KORU Medical Systems, Inc. (the “Company”) to serve as its Chief Financial Officer commencing July 10, 2023.”
KORU Medical Systems, Inc. shareholders approved Ratification of the appointment of independent registered accountants for the 2023 fiscal year. at the 2023-05-17 meeting.
“Proposal 3: Ratification of the appointment of independent registered accountants for the 2023 fiscal year. The Company’s shareholders ratified the appointment of McGrail Merkel Quinn & Associates, P.C. as the company’s independent registered public accountants for the 2023 fiscal year. For Against Abstain Number of Shares 34,150,506 3,284,652 27,402 -”
KORU Medical Systems, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s executive officers. at the 2023-05-17 meeting.
“Proposal 2: Approval, on an advisory basis, of the compensation of the Company’s executive officers. The Company’s shareholders, on an advisory basis, approved the compensation of the company’s executive officers. For Against Abstain Broker Non-Vote Number of Shares 25,941,889 113,998 27,916 11,378,757”
KORU Medical Systems, Inc. shareholders approved Election of Directors at the 2023-05-17 meeting.
“Proposal 1: Election of Directors The nominees for director set forth under “Nominees” below were elected to the Company’s board of directors. Number of Shares Nominees For Withheld Broker Non-Vote R. John Fletcher 23,280,983 2,802,820 11,378,757 Robert A. Cascella 23,391,600 2,692,203 11,378,757 Donna French 26,032,722 51,081 11,378,757 Joseph M. Manko, Jr. 23,009,051 3,074,752 11,378,757 Shahriar (Shar) Matin 26,032,222 51,581 11,378,757 Linda Tharby 26,021,747 62,056 11,378,757”
KORU Medical Systems, Inc. entered into Agreement and Plan of Merger with KORU Medical Systems, Inc., a Delaware corporation (effective 2023-05-16).
“Reincorporation Merger On May 16, 2023 (the “Effective Date”), KORU Medical Systems, Inc., a New York corporation (“KORU Medical NY” or, prior to the Reincorporation (as defined below), the “Company”), effected the change of the Company’s jurisdiction of incorporation from New York to Delaware (the “Reincorporation”) by merging (the “Reincorporation Merger”) with a direct wholly owned subsidiary, KORU Medical Systems, Inc., a Delaware corporation (“KORU Medical DE” or, following the Reincorporation, the “Company”), pursuant to an Agreement and Plan of Merger (the “Reincorporation Merger Agreement”), dated as of May 12, 2023, by and between KORU Medical NY and KORU Medical DE, which is attached hereto as Exhibit 2.1 and incorporated by reference herein.”
KORU Medical Systems, Inc. reported first quarter ended March 31, 2023 results: revenue $7.4 million, net income $2.4 million, EPS $(0.05) per diluted share. Guidance reaffirmed.
“of life for patients, today reported financial results for the first quarter ended March 31, 2023. Highlights: ● First quarter net revenue growth versus prior year of 18% to $7.4 million, marking the sixth consecutive quarter of double-digit growth with strength in all three businesses ● U.S. Core business growth of 15% outpacing the subcutaneous immunoglobulin”
KORU Medical Systems, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $7.3 million, net income Net loss for the fourth quarter of 2022 was $ 2.0 million, EPS $(0.04) per diluted share. Guidance raised.
“fourth quarter and full year ended December 31, 2022. The Company also issued guidance for the full year 2023. Recent Highlights: ● Fourth quarter net revenue growth of 13% to $7.3 million, marking the fifth consecutive quarter of double-digit growth, and full year net revenue growth of 19% to $27.9 million ● Novel Therapies business finished the year with 14 total”
KORU Medical Systems, Inc. reported full year 2022 results: revenue $27.5 to $28.0 million. Guidance raised.
“KORU Medical now expects full year 2022 revenue to be in the range of $27.5 to $28.0 million (previously $27.0 to $27.5 million).”
KORU Medical Systems, Inc. reported the third quarter ended September 30, 2022 results: revenue $7,760,398, net income $1.2 million, EPS $(0.03) per diluted share.
“$ % Net Sales Domestic Core $ 5,900,042 $ 5,076,294 $ 823,748 $ 16.2% International Core 1,096,746 747,281 349,465 46.8% Novel Therapies 763,610 216,969 546,641 251.9% Total $ 7,760,398 $ 6,040,544 $ 1,719,854 $ 28.5% Total net sales increased $1.7 million, or 28.5%, for the three months ended September 30, 2022, as compared with the same period last year as we”
Tom Adams was appointed as Interim Chief Financial Officer at KORU Medical Systems, Inc..
“In the interim, the Company’s Vice President of Financial Planning and Analysis, Tom Adams, will serve as Interim Chief Financial Officer of the Company effective July 1, 2022.”
Karen Fisher departed as Chief Financial Officer at KORU Medical Systems, Inc..
“As reported under Item 1.01 above, Karen Fisher, the Company’s Chief Financial Officer, will resign her employment effective as of June 30, 2022 to pursue other opportunities.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.